Lung Cancer

First-Line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC

As reported in The New England Journal of Medicine by Alice T. Shaw, MD, PhD, and colleagues, an interim analysis of the phase III CROWN trial...

ASCO Announces Julie R. Gralow, MD, FACP, FASCO, as New Chief Medical Officer

Julie R. Gralow, MD, FACP, FASCO, Professor of Medical Oncology and Director of Breast Medical Oncology at the University of Washington...

Gynecologic Cancers

Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer

In a single-institution phase II trial reported in JAMA Oncology, Zsiros et al found that the combination of pembrolizumab with bevacizumab...


FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate

The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee...


ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...


More Top Stories

Gynecologic Cancers

Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair

Hepatobiliary Cancer

ESMO Asia 2020: Futibatinib for Patients With Refractory Intrahepatic Cholangiocarcinoma and FGFR2 Fusions/Rearrangements

Clinical benefit was provided by the FGFR1–4 inhibitor futibatinib in patients with refractory intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements, including those enrolled in Asian countries. These findings were presented by Furuse et al at the ESMO Asia Virtual...


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Supportive Care
Pain Management

Arjun Sahgal, MD, on Reducing the Pain of Spinal Metastases: SBRT vs Palliative Radiotherapy

Breast Cancer

Researchers Develop Prognostic Model to Guide Systemic Therapy for Early-Stage HER2-Positive Breast Cancer

As reported in The Lancet Oncology, Prat et al have developed a prognostic risk score model—HER2DX—that can be used to identify patients with early-stage HER2-positive breast cancer who might be candidates for escalated or de-escalated systemic treatment. As stated by the investigators, “In...


Impact of COVID-19 on Well-Being in the Oncology Workforce: COVID-NOW Survey Results

The results of a survey of 1,038 doctors, nurses, pharmacists, administrators, and allied health professionals (such dietitians and physiotherapists) working in oncology in the United Kingdom’s National Health Service (NHS) during the spring wave of COVID-19 were presented by Susana N. Banerjee,...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Lung Cancer

Masahiro Tsuboi, MD, on NSCLC: Adjuvant Osimertinib in EGFR-Mutated Disease

Solid Tumors

ESMO Asia 2020: Early Detection and Localization of Cancer Using a Blood-Based Assay

The ELSA-seq assay was able to detect diverse cancer types at early stages with high specificity and was able to provide information regarding the tissue of origin, according to findings presented by Gao et al at the ESMO Asia Virtual Congress 2020 (Abstract LBA3). Qiang Gao, MD, PhD, of the Liver...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...